Concord Biotech Ltd approves Q2 FY27 results; consolidated revenue rises 25.1% YoY to ₹309.07 crore
- Consolidated net profit was ₹69.57 crore, up 10.3% YoY; operating margin was approximately 31.1%.
- Board set November 4, 2026 as the record date for the previously declared 1:1 bonus issue.
- Limited-review reports were unmodified; certain subsidiary and joint-venture information in the consolidated report was not reviewed.
Original Filing: https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d31c798c-7d26-444e-9d42-06e77b9cbcc3.pdf